Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen L Chan

Showing results (101-110 of 164) with videos related to

Pageof 17
Sort By:
BMC Cancer|May 13, 2015
Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for responseWinnie Yeo, Stephen L Chan, Frankie K F Mo, et al.
Molecular Cancer Therapeutics|March 1, 2015
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor EverolimusHung Huynh, Huai-Xiang Hao, Stephen L Chan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 22, 2011
Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinomaStephen L Chan, Frankie K F Mo, Vincent W S Wong, et al.
British Journal of Cancer|March 30, 2016
Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI gradeHidenori Toyoda, Paul B S Lai, James O'Beirne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 StudyRichard S Finn, Masatoshi Kudo, Ivan Borbath, et al.
Cancer Research Communications|February 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 StudyStephen L Chan, Thomas Yau, Robin K Kelley, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2015
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patientsPeiyong Jiang, Carol W M Chan, K C Allen Chan, et al.
Thrombosis and Haemostasis|January 30, 2026
Switching Cancer-associated Venous Thromboembolism Treatment from Continuous LMWH to DOACs: An EvaluationWei Kang, Chin-Yao Shen, Michael Chun-Yuan Cheng, et al.
Liver Cancer|October 30, 2023
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 TrialPhilippe Merle, Masatoshi Kudo, Julien Edeline, et al.
Hepatology (Baltimore, Md.)|April 16, 2016
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaAnn-Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, et al.
Pageof 17

Showing results (101-110 of 164) with videos related to

Sort By:
Pageof 17
BMC Cancer|May 13, 2015
Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for responseWinnie Yeo, Stephen L Chan, Frankie K F Mo, et al.
Molecular Cancer Therapeutics|March 1, 2015
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor EverolimusHung Huynh, Huai-Xiang Hao, Stephen L Chan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|November 22, 2011
Use of antiviral therapy in surveillance: impact on outcome of hepatitis B-related hepatocellular carcinomaStephen L Chan, Frankie K F Mo, Vincent W S Wong, et al.
British Journal of Cancer|March 30, 2016
Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI gradeHidenori Toyoda, Paul B S Lai, James O'Beirne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 StudyRichard S Finn, Masatoshi Kudo, Ivan Borbath, et al.
Cancer Research Communications|February 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 StudyStephen L Chan, Thomas Yau, Robin K Kelley, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 4, 2015
Lengthening and shortening of plasma DNA in hepatocellular carcinoma patientsPeiyong Jiang, Carol W M Chan, K C Allen Chan, et al.
Thrombosis and Haemostasis|January 30, 2026
Switching Cancer-associated Venous Thromboembolism Treatment from Continuous LMWH to DOACs: An EvaluationWei Kang, Chin-Yao Shen, Michael Chun-Yuan Cheng, et al.
Liver Cancer|October 30, 2023
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 TrialPhilippe Merle, Masatoshi Kudo, Julien Edeline, et al.
Hepatology (Baltimore, Md.)|April 16, 2016
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinomaAnn-Lii Cheng, Sumitra Thongprasert, Ho Yeong Lim, et al.
Pageof 17